Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial |
| |
| Institution: | 1. The Institute of Cancer Research, London, UK;2. Royal Devon & Exeter NHS Foundation Trust, Exeter, UK;3. Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK;4. Torbay and South Devon NHS Foundation Trust, Torquay, UK;5. Brighton & Sussex University Hospitals NHS Trust, Brighton, UK;6. University of Birmingham, Birmingham, UK;7. Academic unit of Oncology, Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK;8. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK;9. Royal Marsden NHS Foundation Trust, London, UK;1. The Institute of Cancer Research, London, UK;2. Royal Devon & Exeter NHS Foundation Trust, Exeter, UK;3. Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK;4. Torbay and South Devon NHS Foundation Trust, Torquay, UK;5. Brighton & Sussex University Hospitals NHS Trust, Brighton, UK;6. University of Birmingham, Birmingham, UK;7. Academic unit of Oncology, Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK;8. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK;9. Royal Marsden NHS Foundation Trust, London, UK |
| |
| Abstract: | BackgroundBC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer–specific survival from the addition of concomitant 5-fluorouracil and mitomycin C to radiotherapy.ObjectiveTo determine the impact of treatment on the health-related quality of life (HRQoL) of BC2001 participants.Design, setting, and participants458 UK patients with T2-T4a N0 M0 transitional cell carcinoma of the bladder.InterventionPatients were randomised to the chemotherapy comparison (radiotherapy, 178, or chemoradiotherapy, 182); and/or to the radiotherapy comparison (standard, 108, or reduced high-dose volume radiotherapy, 111).Outcome measurements and statistical analysisPatients completed Functional Assessment of Cancer Therapy—Bladder (FACT-BL) questionnaires at baseline, end of treatment (EoT), and 6, 12, 24, 36, 48, and 60 months after radiotherapy. The primary endpoint was change from baseline in the bladder cancer subscale (BLCS) at 12 months.Results and limitationsData were available for 331 (92%) and 204 (93%) participants at baseline and for 192 (54%) and 114 (52%) at 12 months for the chemotherapy and radiotherapy comparisons, respectively. HRQoL declined at EoT (BLCS –5.06 99% confidence interval: –6.12 to –4.00, p < 0.001]; overall FACT-B TOTAL score –8.22 –10.76 to –5.68, p < 0.01]), recovering to baseline at 6 months and remaining similar to baseline subsequently. There was no significant difference between randomised groups at any time point.ConclusionsImmediately following (chemo)radiotherapy, a significant proportion of patients report declines in HRQoL, which improve to baseline after 6 months. Two-thirds of patients report stable or improved HRQoL on long-term follow-up. There is no evidence of impairment in HRQoL resulting from the addition of chemotherapy.Patient summaryQuality of life of bladder cancer patients treated with radiotherapy ± chemotherapy deteriorates during treatment, but improves to at least pretreatment levels within 6 months. Addition of chemotherapy to radiotherapy does not affect patient-reported quality of life. |
| |
| Keywords: | BC2001 Chemoradiotherapy Health-related quality of life Muscle-invasive bladder cancer Patient-reported outcomes Randomised controlled trial |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
